Scope
NICE NG193 separates assessment of all chronic pain from treatment of chronic primary pain in people aged 16 and over. Pain persists or recurs beyond three months, and primary and secondary mechanisms can coexist. Its treatment restrictions apply specifically to chronic primary pain; a condition that explains secondary pain needs its own disease-specific pathway. Assessment, agreed goals, activity and psychological support remain central even when pain intensity does not improve.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Assess the person and revisit the diagnosis
- Offer a person-centred assessment of factors contributing to pain and its effect on daily life. Chronic pain means symptoms persisting or recurring for more than 3 months; primary and secondary pain may coexist. [1]
- Consider chronic primary pain when no clear secondary cause explains the presentation, or the pain or its impact is disproportionate to observable injury or disease. Use clinical judgement with the person when deciding investigations, and reassess the diagnosis if the presentation changes. [1]
- Explore activity, work, sleep, wellbeing, trauma, substance use, relationships and social pressures, alongside coping strengths. In young people aged 16–25, consider family dynamics, education and social or emotional development. [1]
- Acknowledge distress and avoid invalidating pain when tests are normal. Explain that symptoms may fluctuate and quality of life may improve even if pain remains unchanged. [1]
- Agree a care plan around the person’s goals, existing helpful strategies and preferred treatment balance. Discuss potential benefits, harms and uncertainty. Manage explanatory secondary disease using its own guideline; combine approaches through shared decisions when primary and secondary pain coexist. [1]
- Reassess changes or flare-ups, review the care plan and consider investigating new symptoms. A cause for a flare may remain unidentified. [1]
Offer activity and consider psychological approaches
- For chronic primary pain in people aged 16 and over, offer supervised group exercise tailored to needs, preferences and abilities. Encourage ongoing physical activity for longer-term general health. [1]
- Consider acceptance and commitment therapy or pain-focused cognitive behavioural therapy from appropriately trained professionals for chronic primary pain in those aged 16 and over. Do not offer biofeedback for this indication. [1]
- A single acupuncture or dry-needling course may be considered for chronic primary pain in those aged 16 and over only within NICE’s delivery and cost conditions: a trained practitioner at NHS band 7 or equivalent/lower, community delivery and no more than 5 hours of professional time, or another trained practitioner and/or setting at equivalent or lower cost. [1]
- Do not offer TENS, therapeutic ultrasound or interferential therapy for chronic primary pain in people aged 16 and over; NICE found no evidence of benefit for this indication. [1]
Keep medication decisions specific to chronic primary pain
- After discussing benefits and harms, consider amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine or sertraline for chronic primary pain in adults aged 18 and over. Seek specialist advice before considering an antidepressant at ages 16–17. [1]
- Explain that an antidepressant for chronic primary pain may help pain, sleep, quality of life and distress even without depression. [1]
- Do not initiate opioids, NSAIDs, paracetamol, benzodiazepines, antipsychotics or ketamine for chronic primary pain in people aged 16 and over. This is an indication-specific recommendation, not a prohibition on treating a separate condition. [1]
- For chronic primary pain in people aged 16 and over, do not initiate antiepileptics including gabapentinoids, topical or intravenous local anaesthetics, corticosteroid trigger-point injections or combined local-anaesthetic/corticosteroid trigger-point injections. Gabapentinoids and local anaesthetics have an exception only within clinical trials for complex regional pain syndrome. [1]
- For someone already taking a medicine that NICE advises against initiating for chronic primary pain, review it jointly. If there is benefit at a safe dose with few harms, agree safe continuation; with little benefit or significant harm, support reduction and stopping where possible. Discuss withdrawal risks rather than simply discontinuing treatment. [1]
Limitations and use
- This guideline’s management section is for chronic primary pain. Its medicine restrictions must not be extrapolated to all cancer pain, neuropathic pain, acute pain or other explanatory secondary conditions.
- Antidepressant doses, individual contraindications and withdrawal schedules are not specified here. NICE identified the antidepressant indication as off-label in April 2021; this summary does not independently establish current Indian licensing.
- Acupuncture workforce and cost limits reflect the UK health-service setting. Linked guidance on disease-specific pain, dependence and cannabis-based medicines is not reproduced.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 7 April 2021
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- United Kingdom
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.